The Sumatriptan Succinate Injection, cataloged under National Stock Number 6505-01-374-5874, is classified within Federal Supply Class 6505 (Drugs and Biologicals) of the Medical, Dental, and Veterinary Equipment group. The manufacturer of record is Glaxo Wellcome Inc. Government technical data includes 5 specifications, cited from the U.S. Government catalog. The record lists 1 manufacturer part number for this item, enabling identification through both NSN and commercial part number lookups. 6 additional reference documents (drawings, advisory and superseded references) are recorded in the U.S. Government catalog. Current acquisition status: Active. Unit of issue: PG.
| Parameter | Value |
|---|---|
| NSN | 6505-01-374-5874 |
| Primary Part Number | NDC00173-0449-02 |
| Item Name | Sumatriptan Succinate Injection |
| FSC / FSG | 6505 / 65 — Drugs and Biologicals |
| Manufacturer | Glaxo Wellcome Inc |
| Status | ACTIVE |
| Therapeutic Equivalent | TO IMITREX BY GLAXO |
| Primary Container Content Quantity | 2.000 MILLILITERS |
| Primary Container Type | VIAL, SINGLE DOSE |
| Active Medicament Medicinal Strength | 6.000 MILLIGRAMS SUMATRIPTAN SUCCINATE PER 0.5 MILLILITERS |
| Total Primary Container Quantity | 5 |
| Acquisition Status | ACTIVE |
| DEMIL Code | DEMIL A — No Demilitarization Required |
| Hazard | Possible hazard — SDS may be required (DLA HMIC P) |
| Criticality Code | X |
| Unit of Issue | PG |
| Part Number | Manufacturer |
|---|---|
| NDC00173-0449-02 PRIMARY | Glaxo Wellcome Inc (USA) |
| Reference | Meaning |
|---|---|
| IMITREX | 5/1 Secondary reference Glaxo Wellcome Inc |
| NDC00173-0449-02 | 5/9 Secondary reference Cardinal Health 100, Inc. |
| NDC00173-0449-02 | 3/1 Design control — primary reference Amerisourcebergen Drug Corp Dba Amerisourcebergen Drug Corp Div Corporate Office |
| NDC00173-0449-02 | 3/1 Design control — primary reference Veterans Health |
| NDC00173-0449-02 | 5/9 Secondary reference Cardinal Health 100, Inc Dba Bindley Western Tennessee Div |
| IMITREX INJECTION | 5/1 Secondary reference Glaxo Wellcome Inc |
NSN 6505-01-374-5874 is a Sumatriptan Succinate Injection, manufactured by Glaxo Wellcome Inc, classified under FSC 6505, Drugs and Biologicals. Status: active.
NSN 6505-01-374-5874 has 1 manufacturer part number on file: NDC00173-0449-02 (Glaxo Wellcome Inc).
Key specifications for NDC00173-0449-02: Therapeutic Equivalent: TO IMITREX BY GLAXO; Primary Container Content Quantity: 2.000 MILLILITERS; Primary Container Type: VIAL, SINGLE DOSE; Part Name Assigned by Controlling Agency: SUMATRIPTAN SUCCINATE INJECTION 6MG/0.5ML 2ML VIAL 5S. 5 specifications are documented in the U.S. Government catalog.
Possible hazard — SDS may be required (DLA HMIC P). Hazard information on this page is shown exactly as it appears in the DLA record.
U.S. Government catalog: edition PUBLOGDVD v12.0.0 (OCT 2026), edition date 2026-10-01, retrieved 2026-10-16.
U.S. Government catalog: edition PUBLOGDVD v12.0.0 (OCT 2026), edition date 2026-10-01, retrieved 2026-10-18.